ArticleEuropean journal of haematology2026
Advances and Challenges in the Multidisciplinary Treatment of Retroperitoneal Infantile Fibrosarcoma in Early Life.
Article in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND AND
aimsRetroperitoneal Infantile Fibrosarcoma (RIFS) is a rare, locally aggressive pediatric soft tissue tumor. Its retroperitoneal location poses challenges due to proximity and potential invasion of critical structures such as the inferior vena cava (IVC). This study aims to illustrate the range of multidisciplinary management strategies and evolving therapeutic approaches.
methodsWe conducted a retrospective case series of infants diagnosed with RIFS and treated at our tertiary center. Clinical presentation, imaging findings, histopathology, treatment modalities (including chemotherapy, surgery, interventional radiology, targeted therapies), and follow-up data were analyzed.
resultsThree infants with histologically confirmed RIFS were identified, with a median age at diagnosis of 2 months (range: 0-8 months). Diagnosis was established through open surgical biopsy. Management was individualized and multimodal, including neoadjuvant chemotherapy, surgical resection, interventional radiology procedures for symptom control, and, in the most recent case, targeted molecular therapy guided by genetic profiling.
conclusionsManagement of RIFS has significantly evolved over the last decade. Advances in surgical techniques combined with the integration of interventional radiology and novel targeted therapies allow a nuanced balance between maximizing oncological control and minimizing surgical morbidity. Multidisciplinary individualized treatment is essential to optimize outcomes in this rare and challenging pediatric tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.